Toxin News and Research

RSS

MIT researchers use disarmed version of anthrax toxin to deliver cancer drugs

Bacillus anthracis bacteria have very efficient machinery for injecting toxic proteins into cells, leading to the potentially deadly infection known as anthrax. A team of MIT researchers has now hijacked that delivery system for a different purpose: administering cancer drugs.

26 Sep 2014

Three institutions collaborate to develop vaccine to treat pneumonia

The long-observed association between pneumonia and heart failure now has more physical evidence, thanks to research in the School of Medicine at The University of Texas Health Science Center at San Antonio.

26 Sep 2014

Leicester scientists lend a helping hand in fight against Alzheimer's and cancer

Chemists at the University of Leicester have reported a breakthrough in techniques to develop new drugs in the fight against diseases such as cancer and Alzheimer's.

24 Sep 2014

Researchers reveal how humans get infected with cholera

Karl Klose, professor of biology and a researcher in UTSA's South Texas Center for Emerging Infectious Diseases, has teamed up with researchers at Ruhr University in Bochum, Germany to understand how humans get infected with cholera.

24 Sep 2014

Elusys completes phase 3 clinical program of obiltoxaximab in healthy adult volunteers

Elusys Therapeutics, Inc., a biopharmaceutical company developing antibody therapies to treat infectious disease, today announced it has completed three phase 3 healthy adult volunteer safety studies of obiltoxaximab (ETI-204).

23 Sep 2014

Soligenix awarded $24.7 million contract to advance development of Rivax vaccine

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that it has been awarded a contract valued at up to $24.7 million inclusive of options by the US Department of Health and Human Service's National Institutes of Health (specifically funded by the National Institute of Allergy and Infectious Diseases or NIAID).

19 Sep 2014

Synthetic Biologics' SYN-005 antibody gets FDA Orphan Drug designation for Pertussis treatment

Synthetic Biologics, Inc., a biotechnology company developing novel anti-infective biologic and drug programs targeting specific pathogens that cause serious infections and diseases, announced today that the U.S. Food and Drug Administration has granted Orphan Drug designation to the Company's proprietary SYN-005 monoclonal antibody (mAb) combination for the treatment of Pertussis, more commonly known as whooping cough.

15 Sep 2014

Center Director of Omni Eye Surgery describes promising option for managing lid disease

Omni Eye Services, a leading provider of ophthalmologic services at five locations in New York and New Jersey, today announced that Dr. Katherine M Mastrota, Center Director of Omni Eye Surgery in New York City, has written a treatment update for Contact Lenses Today describing a promising "new option for managing lid disease."

9 Sep 2014

Cholera against cholera: an interview with Dr Bruce Turnbull, University of Leeds

Cholera bacteria, and other types of bacteria that cause diarrheal diseases, infect your intestines where they release AB5 protein toxins – that is they have a single toxic A-subunit that is linked to a pentamer of B-subunits that act as the delivery vehicle to transport the A-subunit into the cells.

8 Sep 2014

Soligenix announces promising preliminary results from study on ricin toxin vaccine

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today promising preliminary results from a preclinical study with its ricin toxin vaccine RiVax™, in a non-human primate (NHP) lethal aerosol exposure model.

2 Sep 2014

Gene therapy may offer significant advantages in prevention of botulism exposure

The current method to treat acute toxin poisoning is to inject antibodies, commonly produced in animals, to neutralize the toxin. But this method has challenges ranging from safety to difficulties in developing, producing and maintaining the anti-serums in large quantities.

30 Aug 2014

OMRF receives $14.5 million grant from NIH to continue research on anthrax

The National Institutes of Health has awarded the Oklahoma Medical Research Foundation a five-year, $14.5 million grant to continue its research on anthrax and the bacteria's effects on humans.

21 Aug 2014

Modified C. novyi-NT bacterium produces precisely targeted anti-tumor response

A modified version of the Clostridium novyi (C. novyi-NT) bacterium can produce a strong and precisely targeted anti-tumor response in rats, dogs and now humans, according to a new report from Johns Hopkins Kimmel Cancer Center researchers.

14 Aug 2014

Bee, snake, scorpion venom could form basis of new generation of cancer-fighting drugs

Bee, snake or scorpion venom could form the basis of a new generation of cancer-fighting drugs, scientists will report here today.

12 Aug 2014

Inovio Pharmaceuticals reports increased revenue in second quarter 2014

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended June 30, 2014. Total revenue was $3.8 million and $6.2 million for the three and six months ended June 30, 2014, compared to $786,000 and $2.2 million for the same periods in 2013.

11 Aug 2014

Soligenix demonstrates improved immunogenicity and rapid action of anthrax vaccine, VeloThrax

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today results demonstrating the improved immunogenicity and rapid action of its anthrax vaccine, VeloThrax™.

7 Aug 2014

Toxin News and Research

MIT researchers use disarmed version of anthrax toxin to deliver cancer drugs

Three institutions collaborate to develop vaccine to treat pneumonia

Leicester scientists lend a helping hand in fight against Alzheimer's and cancer

Researchers reveal how humans get infected with cholera

Elusys completes phase 3 clinical program of obiltoxaximab in healthy adult volunteers

Soligenix awarded $24.7 million contract to advance development of Rivax vaccine

Synthetic Biologics' SYN-005 antibody gets FDA Orphan Drug designation for Pertussis treatment

Center Director of Omni Eye Surgery describes promising option for managing lid disease

Cholera against cholera: an interview with Dr Bruce Turnbull, University of Leeds

Soligenix announces promising preliminary results from study on ricin toxin vaccine

Gene therapy may offer significant advantages in prevention of botulism exposure

OMRF receives $14.5 million grant from NIH to continue research on anthrax

Modified C. novyi-NT bacterium produces precisely targeted anti-tumor response

Bee, snake, scorpion venom could form basis of new generation of cancer-fighting drugs

Inovio Pharmaceuticals reports increased revenue in second quarter 2014

Soligenix demonstrates improved immunogenicity and rapid action of anthrax vaccine, VeloThrax

Cancer fighter may also help patients survive pneumonia

Plastic surgeons consider themselves the most capable injectors, shows study

Little-known supportive cells in brain may play major role in cognitive function

Non-endoscopic procedure effective in treating severe chronic migraine headaches

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News